GLP Med Compare Tool
The GLP Med Compare Tool helps you compare GLP-1 and related weight-loss medicines using trial results, dose context, treatment type and country approval status. Use it as an evidence guide, not as medical advice or a personal weight-loss prediction.
Compare GLP medicines side by side
Select your country, compare medicines and check whether each figure is a direct trial result or an estimated dose figure.
Weight-loss medicines compared, using clinical-trial data
This tool compares medicines used for weight management by the average weight change seen in published Phase 3 clinical trials, alongside how each is taken and whether it is approved in United Kingdom. Trial averages are not predictions: results and side effects vary from person to person, and a medicine that suits one person may not suit another. This page is information, not medical advice. Last reviewed: July 2026.
| Medicine | Active ingredient | Drug class | Average in trials | How it is taken | Approval |
|---|---|---|---|---|---|
| Mounjaro | tirzepatide | Dual GIP + GLP-1 agonist | −20.9% | Once-weekly injection (pre-filled pen) | Approved for weight management |
| Retatrutide | retatrutide | Triple GIP + GLP-1 + glucagon | −28.3% | Once-weekly injection | In clinical trials |
| Wegovy injection | semaglutide | GLP-1 receptor agonist | −18.7% | Once-weekly injection (pre-filled pen) | Approved for weight management |
| Wegovy pill | oral semaglutide 25 mg | GLP-1 receptor agonist | −13.6% | Daily tablet | Approved for weight management |
| Foundayo | orforglipron | GLP-1 receptor agonist (small molecule) | −11.2% | Daily tablet | Under regulatory review |
| Saxenda | liraglutide 3.0 mg | GLP-1 receptor agonist | −8.0% | Once-daily injection (pre-filled pen) | Approved for weight management |
| Mysimba | naltrexone / bupropion | Appetite + reward pathway (non-GLP-1) | −5.0% | Daily tablets (up to 2 twice daily) | Approved for weight management |
| Orlistat | orlistat | Gut lipase inhibitor (non-GLP-1) | −5.0% | Capsule with each main meal (up to 3×/day) | Approved for weight management |
| CagriSema | cagrilintide / semaglutide | Amylin analogue + GLP-1 | −20.4% | Once-weekly injection | In clinical trials |
| Rybelsus | oral semaglutide (diabetes) | GLP-1 receptor agonist | ~4.0% (estimated) | Daily tablet | Approved for type 2 diabetes only |
| Qsymia | phentermine / topiramate | Stimulant + anticonvulsant (non-GLP-1) | −9.8% | Daily capsule | Not available |
Evidence & sources
Figures are drawn from peer-reviewed Phase 3 trials including SURMOUNT, STEP, OASIS-4, ATTAIN-1, TRIUMPH, SCALE, the COR programme, XENDOS, REDEFINE 1, PIONEER and CONQUER, together with regulator materials (MHRA, NICE, FDA, EMA). Some doses are estimated by interpolation between studied doses and are marked as estimates.
What does the GLP Med Compare Tool compare? Trial data, medicine type and country status.
The tool compares weight-loss medicines such as semaglutide, tirzepatide, liraglutide, orforglipron, retatrutide, CagriSema and other related treatments.
How should I read the figures? Direct results are stronger than estimates.
Some figures come directly from published or reported clinical trial results. Others may be estimated from nearby studied doses where no dose-specific trial result is available.
For example, if trial results exist for 5 mg and 10 mg, a 7.5 mg figure may be estimated between those doses. That can help with comparison, but it is not the same as a confirmed 7.5 mg trial result.
How do I compare results fairly? Study length, dose and patient groups matter.
Trial results are useful, but they are not always simple to compare. One study may run longer than another, use a different dose, or include people with different starting weights and health backgrounds.
Treat the figures as a guide to the evidence. They should not be read as a ranking, promise, shopping list or prediction of your own result.
Safety notes for upcoming medicines Trial attention does not mean legal availability.
New weight-loss medicines can attract attention long before they are approved. A trial result, press release or estimated dose comparison does not mean a medicine is available, legal to buy or safe to source online.
What is the GLP Med Compare Tool? A quick explanation of the tool.
It is an educational Monj tool that compares GLP-1 and related weight-loss medicines using clinical trial data, estimated dose figures, treatment type and approval status by country.
Are all figures direct clinical trial results? No. Some may be estimates.
No. Some figures may come directly from clinical trials, while others may be estimated from nearby studied doses. Estimated figures should be treated as context only.
Does the tool tell me which medicine to take? No. It does not replace clinical advice.
No. The tool does not recommend treatment. It helps you understand the evidence before speaking to a qualified clinician or pharmacist.
Can trial averages predict my own result? No. Individual results vary.
No. Trial averages describe what happened across a study group. Your own result may be higher, lower or very different.
Why does the country selector matter? Approval and availability are local.
Medicine approval and availability are not the same everywhere. A medicine may be approved in one country, under review in another and unavailable somewhere else.
Page status: educational information only. Last reviewed July 2026. Monj does not sell, prescribe or dispense medicines. Some dose figures may be estimated from nearby clinical trial data. Approval status and availability can vary by country.